H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs Tris Pharma, Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
Tris Pharma, Inc.
NJRank #FEIN 22-3747409

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPTris Pharma, Inc.
Total filings80,813241
Certified %98.23%93.78%
Denied %1.09%1.66%
Withdrawn %0.61%3.73%
Cert-withdrawn %0.07%0.83%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePANJ

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — Tris Pharma, Inc.

DOL case-status mix.

Outcome breakdown: Certified 93.8%, Cert-withdrawn 0.8%, Withdrawn 3.7%, Denied 1.7%
Outcome breakdown
OutcomeShare
Certified93.8%
Cert-withdrawn0.8%
Withdrawn3.7%
Denied1.7%
Certified93.8%
Cert-withdrawn0.8%
Withdrawn3.7%
Denied1.7%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
Tris Pharma, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20108
FY201115
FY201217
FY201316
FY201420
FY201518
FY201619
FY201717
FY201818
FY201915
FY20207
FY20215
FY20223
FY20238
FY202422
FY202518
FY202615

Top 5 occupations — Deloitte Consulting LLP

Top 5 occupations — Tris Pharma, Inc.

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.